Demonstrate Antibody ADCC Activity Through the mFcγRIV Receptor
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action (MOA) of antibodies that target virus-infected or diseased (e.g., tumor) cells for destruction by components of the cell-mediated immune system. Mouse FcγRIV (mFcγRIV) is the predominant receptor involved in ADCC in the mouse and is more closely related to human FcγRIIIa, the primary Fc receptor involved in ADCC in humans, than mFcγRIII.
The mFcγRIV ADCC Reporter Bioassay is a biologically relevant MOA-based assay that can be used to measure the activity of mouse antibodies that specifically bind and activate FcγRIV. Mouse IgG2a, and to a lesser extent IgG2b, are known to mediate ADCC through the activation of mFcγRIV. In contrast, mouse IgG1 does not bind to mFcγIV. The bioassay overcomes the limitations of more labor-intensive and highly variable primary cell assays. The bioassay workflow is simple and robust, compatible with 96-well and 384-well plate formats and, unlike traditional primary cell-based assays, provides a quantitative measure of ADCC with low variability and high accuracy.
mFcγRIV ADCC Bioassay Effector Cells, Propagation Model, allows propagation and banking of the mFcγRIV Effector Cells. Bio-Glo™ Luciferase Assay System is the required reagent for use with mFcγRIV ADCC Bioassay Effector Cells, Propagation Model.